| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Giuseppe Alberto Palumbo | Q61037582 |
| P2093 | author name string | Francesca Palandri | |
| Francesco Mendicino | |||
| Claudia Baratè | |||
| Elena Maria Elli | |||
| P2860 | cites work | Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib | Q26750696 |
| Jakpot! New small molecules in autoimmune and inflammatory diseases | Q27001957 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Regulatory T cells exert checks and balances on self tolerance and autoimmunity | Q28267935 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis | Q33397838 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. | Q33410346 | ||
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | Q33420037 | ||
| Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder. | Q33420865 | ||
| Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial | Q33432637 | ||
| Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study | Q33437373 | ||
| Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial | Q33439559 | ||
| Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients | Q33440405 | ||
| Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 | ||
| Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 | ||
| An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor | Q34343220 | ||
| Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. | Q34420372 | ||
| Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. | Q34434935 | ||
| The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis | Q36091279 | ||
| Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback | Q36238033 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade | Q37679267 | ||
| Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond | Q37833893 | ||
| American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Q38275215 | ||
| Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. | Q38393343 | ||
| Immunological Consequences of JAK Inhibition: Friend or Foe? | Q38570383 | ||
| Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib | Q38719157 | ||
| Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery | Q38862771 | ||
| Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. | Q38938526 | ||
| Novel targets in the treatment of chronic graft-versus-host disease | Q39023963 | ||
| The promise of Janus kinase inhibitors in the treatment of hematological malignancies | Q39170500 | ||
| Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. | Q40235276 | ||
| Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. | Q40741460 | ||
| Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. | Q40742224 | ||
| JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 | ||
| JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 | ||
| JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells | Q41160178 | ||
| JAK inhibitors and myelofibrosis, Einstein and ruxolitinib | Q42660823 | ||
| The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
| Progressive multifocal leukoencephalopathy associated with ruxolitinib | Q44509111 | ||
| Bilateral toxoplasmosis retinitis associated with ruxolitinib | Q44909357 | ||
| Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. | Q45350105 | ||
| Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. | Q46891342 | ||
| Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis. | Q47114304 | ||
| Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages | Q47334119 | ||
| JAK inhibition as a therapeutic strategy for immune and inflammatory diseases | Q47439880 | ||
| The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium | Q47581193 | ||
| Ruxolitinib-associated infections: A systematic review and meta-analysis. | Q48278553 | ||
| Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. | Q51733623 | ||
| Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. | Q52721155 | ||
| The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. | Q53095310 | ||
| Topical Ruxolitinib for the Treatment of Alopecia Universalis. | Q54229292 | ||
| Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? | Q54393708 | ||
| Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. | Q54533845 | ||
| Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial | Q56335282 | ||
| Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge | Q56970836 | ||
| Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy | Q57075545 | ||
| The Role of New Technologies in Myeloproliferative Neoplasms | Q64085216 | ||
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 | ||
| The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders | Q79805830 | ||
| SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage | Q82674325 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy | Q91842389 | ||
| Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study | Q92382938 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | ruxolitinib | Q7383611 |
| P304 | page(s) | 1186 | |
| P577 | publication date | 2019-11-07 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib | |
| P478 | volume | 9 |
| Q98726025 | COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey |
| Q96618090 | COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking |
| Q97522230 | Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing |
| Q97069845 | How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey |
| Q104558729 | Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA |
| Q91522442 | Treatment and unmet needs in steroid-refractory acute graft-versus-host disease |
| Q92060483 | Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib |
Search more.